Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea · Delayed Price · Currency is KRW 4,170.00
-265.00 (-5.98%)
Last updated: Jun 8, 2026, 1:53 PM KST
Bukwang Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 200,684 | 200,714 | 160,087 | 125,928 | 190,909 | 182,491 |
Other Revenue | 0 | - | - | -0 | -0 | - |
| 200,684 | 200,714 | 160,087 | 125,928 | 190,909 | 182,491 | |
Revenue Growth (YoY) | 15.67% | 25.38% | 27.13% | -34.04% | 4.61% | 7.56% |
Cost of Revenue | 111,020 | 109,186 | 86,023 | 79,012 | 111,763 | 106,942 |
Gross Profit | 89,664 | 91,528 | 74,064 | 46,916 | 79,147 | 75,550 |
Selling, General & Admin | 55,380 | 55,645 | 45,966 | 51,274 | 49,797 | 43,477 |
Research & Development | 19,512 | 19,401 | 23,431 | 34,551 | 24,274 | 22,465 |
Amortization of Goodwill & Intangibles | 637.6 | 558.7 | 114.77 | 31.86 | 33.49 | 31.76 |
Other Operating Expenses | 505.48 | 470.86 | 2,225 | 2,078 | 1,345 | 1,317 |
Operating Expenses | 77,410 | 77,364 | 72,447 | 84,413 | 79,377 | 69,928 |
Operating Income | 12,254 | 14,164 | 1,618 | -37,497 | -230.64 | 5,622 |
Interest Expense | -3,895 | -3,895 | -6,490 | -3,808 | -1,760 | -1,408 |
Interest & Investment Income | 4,711 | 4,711 | 4,419 | 3,080 | 1,440 | 268.16 |
Earnings From Equity Investments | 18.46 | 18.33 | 343.13 | -1,501 | 58.57 | -1,361 |
Currency Exchange Gain (Loss) | -444.43 | -444.43 | -64.59 | -177.44 | 88.47 | 322.31 |
Other Non Operating Income (Expenses) | 4,728 | 409.71 | -1,755 | 867.73 | -113.73 | 33.63 |
EBT Excluding Unusual Items | 17,372 | 14,963 | -1,930 | -39,036 | -517.65 | 3,477 |
Impairment of Goodwill | -418.17 | -418.17 | -915.64 | - | - | - |
Gain (Loss) on Sale of Investments | -6,009 | -6,009 | 738.9 | -564.4 | -567.47 | 90.53 |
Gain (Loss) on Sale of Assets | 374.4 | 374.4 | 53.75 | 30.64 | 52.25 | 220.05 |
Asset Writedown | -2,524 | -2,524 | -8,670 | - | - | - |
Other Unusual Items | - | - | 7,753 | - | - | - |
Pretax Income | 8,795 | 6,386 | -2,970 | -39,569 | -1,033 | 3,787 |
Income Tax Expense | -4,911 | -6,047 | 489.25 | -5,163 | 3,216 | 6,584 |
Earnings From Continuing Operations | 13,706 | 12,433 | -3,459 | -34,407 | -4,249 | -2,797 |
Minority Interest in Earnings | 98.44 | 124.48 | 817.44 | 3,077 | 1,774 | 1,880 |
Net Income | 13,804 | 12,558 | -2,641 | -31,330 | -2,475 | -916.62 |
Net Income to Common | 13,804 | 12,558 | -2,641 | -31,330 | -2,475 | -916.62 |
Shares Outstanding (Basic) | 86 | 83 | 68 | 68 | 68 | 68 |
Shares Outstanding (Diluted) | 86 | 83 | 68 | 68 | 68 | 68 |
Shares Change (YoY) | 45.42% | 21.97% | -1.06% | - | -0.01% | -0.25% |
EPS (Basic) | 160.08 | 152.01 | -39.00 | -457.67 | -36.15 | -13.39 |
EPS (Diluted) | 160.08 | 152.01 | -39.00 | -458.00 | -36.15 | -13.39 |
Free Cash Flow | 5,044 | 14,206 | 32,424 | -12,196 | 12,163 | 25,740 |
Free Cash Flow Per Share | 58.49 | 171.97 | 478.75 | -178.17 | 177.69 | 375.98 |
Gross Margin | 44.68% | 45.60% | 46.27% | 37.26% | 41.46% | 41.40% |
Operating Margin | 6.11% | 7.06% | 1.01% | -29.78% | -0.12% | 3.08% |
Profit Margin | 6.88% | 6.26% | -1.65% | -24.88% | -1.30% | -0.50% |
Free Cash Flow Margin | 2.51% | 7.08% | 20.25% | -9.69% | 6.37% | 14.11% |
EBITDA | 17,955 | 19,652 | 5,724 | -33,204 | 4,886 | 10,465 |
EBITDA Margin | 8.95% | 9.79% | 3.57% | -26.37% | 2.56% | 5.73% |
D&A For EBITDA | 5,701 | 5,489 | 4,106 | 4,292 | 5,117 | 4,843 |
EBIT | 12,254 | 14,164 | 1,618 | -37,497 | -230.64 | 5,622 |
EBIT Margin | 6.11% | 7.06% | 1.01% | -29.78% | -0.12% | 3.08% |
Effective Tax Rate | - | - | - | - | - | 173.85% |
Advertising Expenses | - | 9,018 | 6,307 | 12,764 | 12,181 | 6,622 |